Preclinical studies demonstrated that HER2 signaling largely relies on p110α rather than on other class-I PI3K isoforms [92], thus providing a strong rationale for therapeutic intervention and targeting of PIK3CA in HER2+ breast tumors. This evidence concerns the gene ERBB2 and breast neoplasm.